




# Quantib



# intrasense®

Press  
release

Montpellier, December 11, 2017 - 5:45 pm CET

## Intrasense and Quantib sign a commercial agreement

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Quantib, spin-off from *Erasmus University Medical Center* (Rotterdam - The Netherlands), announce the signing of a distribution agreement for Myrian®. The new partners joined forces to accelerate Quantib's product development, resulting in their FDA and CE approved product Quantib™ ND, based on the Myrian® platform.

### A high value-added partnership serving innovation

Quantib has been collaborating closely with Intrasense since 2016, developing this new medical imaging software dedicated to neurodegenerative diseases. Using [Myrian® Studio](#), Quantib team accelerated the creation of the Quantib™ ND application. A distribution agreement is promoting Myrian® as platform of this innovative neuro application.

Quantib™ ND is a FDA approved and CE marked imaging software solution, offering clinicians fast and accurate automated brain segmentation. Myrian® Studio perfectly matched R&D requirements, as a customizable industrial solution for development, enabling an optimal time-to-market.

### Developing a high-tech application for neurology

Based on the Myrian® platform, Quantib™ ND provides a high-tech user-friendly general workstation including a variety of MRI brain scan analyses. It proposes a state of the art imaging solution for quantification, analysis and reporting in neurology.

*Rudolf Scholte, CEO of Quantib, comments: «Collaborating with Intrasense provided us the opportunity to bring our brain segmentation solution to the market using a well-known and easy-to-use platform. The integration of Quantib™ ND with Myrian® Studio allows the user to deploy our advanced machine learning algorithms in a user-friendly environment. »*

*« This collaboration with Quantib is a very interesting partnership, supporting them in developing their technical solution and market offer for visualization technologies and medical imaging analysis. Myrian® Studio perfectly meets their needs, offering turn-key and optimized time-to-market solutions. »* adds Nicolas Reymond, Director of Business Development & Operations at Intrasense.



### About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

For more information, please visit [www.intrasense.fr](http://www.intrasense.fr).

### About Quantib BV

Quantib strives for faster and more accurate diagnoses, supporting adequate and timely patientcare. Using advanced machine learning techniques, Quantib's products can detect changes in tissue sooner than would be possible with the naked eye. Quantib has multiple machine learning products with an FDA and/or CE certification. These products are focused on the diagnosis of Alzheimer's Disease and Multiple Sclerosis. During 2017, Quantib not only was announced as winner of The Dutch Data Science prize, but also secured €4.5M in funding to scale-up their business.

For more information, please visit [www.quantib.com](http://www.quantib.com).

### Contacts

Intrasense  
Stéphane Chemouny  
Chairman and Chief Executive Officer  
Christophe Lamboeuf  
Deputy Managing Director  
Tel: +33 4 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor Relations and Financial  
Communication  
Valentine Brouchet  
Pierre Laurent  
Tel: + 33 1 44 71 94 96  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

